Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 35.20

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	6/25/2002 7:47:43 AM
From: mopgcw	Read Replies (1) of 566

Dane Pharmexa and U.S. Rigel settle patent dispute COPENHAGEN, June 24 (Reuters) - Danish biotech firm Pharmexa said on Monday its subsidiary Inoxell had entered an agreement with U.S. rival Rigel Pharmaceuticals to end a patent dispute over drug target identification technologies. "The agreement involves both cross-licensing and joint ownership to certain patents and allows for worldwide freedom of operation for both companies," Pharmexa said in a statement. The financial terms of the deal were not disclosed. "We are happy to have reached a settlement with Rigel that allows both of our companies to concentrate our efforts on drug target identification," Inoxell Chief Executive Officer Peter Kristensen said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next